3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
867
Carcinoma, Non-Small-Cell Lung
637
Prostatic Neoplasms
516
Multiple Myeloma
441
Neoplasms
425
Leukemia, Myeloid, Acute
377
Lymphoma
356
Leukemia
335
Melanoma
333
Neoplasm Metastasis
321
Lung Neoplasms
308
Lymphoma, Non-Hodgkin
302
Leukemia, Lymphocytic, Chronic, B-Cell
301
Colorectal Neoplasms
281
Ovarian Neoplasms
264
Pancreatic Neoplasms
249
Recurrence
240
Precursor Cell Lymphoblastic Leukemia-Lymphoma
239
Myelodysplastic Syndromes
233
Glioblastoma
212
Hodgkin Disease
201
Lymphoma, Large B-Cell, Diffuse
197
Lymphoma, Follicular
195
Brain Neoplasms
194
Carcinoma, Renal Cell
189
Head and Neck Neoplasms
187
Squamous Cell Carcinoma of Head and Neck
186
Lymphoma, Mantle-Cell
171
Sarcoma
158
Fallopian Tube Neoplasms
139
Interventions
enzalutamide
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has results
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts